Medpace Holdings Faces Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy MEDP?
Source: Globenewswire
- Lawsuit Background: Levi & Korsinsky LLP has notified investors that Medpace Holdings, Inc. is facing a class action lawsuit aimed at recovering losses for investors affected between April 22, 2025, and February 9, 2026.
- False Statements: The lawsuit alleges that defendants made overwhelmingly positive statements while concealing significant adverse facts regarding Medpace's backlog cancellation rate, leading to overly optimistic growth expectations among investors.
- Performance Decline: On February 9, 2026, Medpace reported a fourth-quarter book-to-bill ratio of 1.04, significantly below the guidance of 1.15, causing the stock price to plummet from $530.35 to $446.05, a decline of over 15.9%.
- Investor Rights: Affected investors have until June 8, 2026, to request to be appointed as lead plaintiff, with participation in any recovery requiring no out-of-pocket costs, highlighting the firm's commitment to protecting investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 501.230
Low
462.00
Averages
569.17
High
660.00
Current: 501.230
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Holdings Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Medpace Holdings (NASDAQ: MEDP) securities between April 22, 2025, and February 9, 2026, highlighting concerns over the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that Medpace misled investors regarding its expected book-to-bill ratio during earnings calls, claiming a ratio of 1.15, while the actual reported ratio was only 1.04, leading to a loss of investor confidence.
- Stock Price Volatility: Following the announcement of the disappointing book-to-bill ratio on February 9, 2026, Medpace's stock plummeted from $530.35 per share to $446.05 per share, a decline of over 15.9%, reflecting market disappointment in the company's outlook.
- Shareholder Action Guidance: Shareholders are advised to submit their papers by June 8, 2026, to serve as lead plaintiffs in the class action, emphasizing the importance of corporate governance and shareholder rights.
See More
Medpace Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Medpace, alleging securities fraud or other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by June 8, 2026, indicating significant legal risks that could impact the company's reputation.
- Poor Earnings Report: Medpace's fourth quarter 2025 earnings, released on February 9, 2026, revealed a book-to-bill ratio of 1.04, significantly below the company's guidance, reflecting weak business growth that may lead to declining investor confidence.
- Stock Price Volatility: Following the earnings report, Medpace's stock price plummeted by $84.30, or 15.9%, closing at $446.05 on February 10, 2026, highlighting market concerns regarding the company's future prospects.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class litigation with a long history of recovering multimillion-dollar damages for victims, suggests that this lawsuit could have profound implications for Medpace's financial health and market performance.
See More
Medpace Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Medpace Holdings, Inc., aiming to recover damages for investors who purchased securities between April 22, 2025, and February 9, 2026, reflecting strong investor dissatisfaction with the company's financial transparency.
- False Statement Allegations: The complaint alleges that Medpace exaggerated its book-to-bill ratio of 1.15 during earnings calls while failing to disclose contrary internal information, leading investors to misunderstand the company's operations and financial outlook, which could negatively impact stock performance.
- Investor Rights Protection: Affected investors have until June 5, 2026, to apply as lead plaintiffs, underscoring the legal team's commitment to safeguarding investor rights and highlighting the potential impact of the class action.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm that has recovered hundreds of millions for investors, demonstrating its expertise and successful track record in securities fraud cases.
See More
Medpace Holdings Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Medpace Holdings for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026, with a deadline to contact the firm by June 5, 2026.
- False Statements Exposed: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its share price, which led to significant investor losses once the market uncovered the truth about the company's performance.
- Opportunity for Loss Recovery: Affected shareholders are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to help investors understand their rights and participate in claims.
- Lawsuit Status Clarification: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially forfeiting their chance for recovery.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Reminder: DJS Law Group reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act during the trading period from April 22, 2025, to February 9, 2026.
- False Statements Exposed: The complaint alleges that Medpace made overly positive statements to the market, yet later revealed a lower-than-expected book-to-bill ratio, citing the highest cancellation rates in over a year, indicating that their public statements were materially misleading.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in the lawsuit for potential recovery, noting that appointment as lead plaintiff is not required to partake in any recovery, highlighting the accessibility of legal recourse.
- Lawsuit Deadline: The deadline for this case is June 5, 2026, and investors must act before this date to protect their rights and seek compensation for their losses.
See More
Medpace Holdings Faces Class Action Lawsuit
- Lawsuit Background: Levi & Korsinsky LLP has notified investors that Medpace Holdings, Inc. is facing a class action lawsuit aimed at recovering losses for investors affected between April 22, 2025, and February 9, 2026.
- False Statements: The lawsuit alleges that defendants made overwhelmingly positive statements while concealing significant adverse facts regarding Medpace's backlog cancellation rate, leading to overly optimistic growth expectations among investors.
- Performance Decline: On February 9, 2026, Medpace reported a fourth-quarter book-to-bill ratio of 1.04, significantly below the guidance of 1.15, causing the stock price to plummet from $530.35 to $446.05, a decline of over 15.9%.
- Investor Rights: Affected investors have until June 8, 2026, to request to be appointed as lead plaintiff, with participation in any recovery requiring no out-of-pocket costs, highlighting the firm's commitment to protecting investor rights.
See More
Medpace Holdings Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Medpace Holdings (NASDAQ: MEDP) securities between April 22, 2025, and February 9, 2026, highlighting concerns over the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that Medpace misled investors regarding its expected book-to-bill ratio during earnings calls, claiming a ratio of 1.15, while the actual reported ratio was only 1.04, leading to a loss of investor confidence.
- Stock Price Volatility: Following the announcement of the disappointing book-to-bill ratio on February 9, 2026, Medpace's stock plummeted from $530.35 per share to $446.05 per share, a decline of over 15.9%, reflecting market disappointment in the company's outlook.
- Shareholder Action Guidance: Shareholders are advised to submit their papers by June 8, 2026, to serve as lead plaintiffs in the class action, emphasizing the importance of corporate governance and shareholder rights.
See More
Medpace Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Medpace, alleging securities fraud or other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by June 8, 2026, indicating significant legal risks that could impact the company's reputation.
- Poor Earnings Report: Medpace's fourth quarter 2025 earnings, released on February 9, 2026, revealed a book-to-bill ratio of 1.04, significantly below the company's guidance, reflecting weak business growth that may lead to declining investor confidence.
- Stock Price Volatility: Following the earnings report, Medpace's stock price plummeted by $84.30, or 15.9%, closing at $446.05 on February 10, 2026, highlighting market concerns regarding the company's future prospects.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class litigation with a long history of recovering multimillion-dollar damages for victims, suggests that this lawsuit could have profound implications for Medpace's financial health and market performance.
See More
Medpace Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Medpace Holdings, Inc., aiming to recover damages for investors who purchased securities between April 22, 2025, and February 9, 2026, reflecting strong investor dissatisfaction with the company's financial transparency.
- False Statement Allegations: The complaint alleges that Medpace exaggerated its book-to-bill ratio of 1.15 during earnings calls while failing to disclose contrary internal information, leading investors to misunderstand the company's operations and financial outlook, which could negatively impact stock performance.
- Investor Rights Protection: Affected investors have until June 5, 2026, to apply as lead plaintiffs, underscoring the legal team's commitment to safeguarding investor rights and highlighting the potential impact of the class action.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm that has recovered hundreds of millions for investors, demonstrating its expertise and successful track record in securities fraud cases.
See More
Medpace Holdings Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Medpace Holdings for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026, with a deadline to contact the firm by June 5, 2026.
- False Statements Exposed: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its share price, which led to significant investor losses once the market uncovered the truth about the company's performance.
- Opportunity for Loss Recovery: Affected shareholders are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to help investors understand their rights and participate in claims.
- Lawsuit Status Clarification: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially forfeiting their chance for recovery.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Reminder: DJS Law Group reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act during the trading period from April 22, 2025, to February 9, 2026.
- False Statements Exposed: The complaint alleges that Medpace made overly positive statements to the market, yet later revealed a lower-than-expected book-to-bill ratio, citing the highest cancellation rates in over a year, indicating that their public statements were materially misleading.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in the lawsuit for potential recovery, noting that appointment as lead plaintiff is not required to partake in any recovery, highlighting the accessibility of legal recourse.
- Lawsuit Deadline: The deadline for this case is June 5, 2026, and investors must act before this date to protect their rights and seek compensation for their losses.
See More
Medpace Holdings Faces Class Action Lawsuit
- Lawsuit Background: Levi & Korsinsky LLP has notified investors that Medpace Holdings, Inc. is facing a class action lawsuit aimed at recovering losses for investors affected between April 22, 2025, and February 9, 2026.
- False Statements: The lawsuit alleges that defendants made overwhelmingly positive statements while concealing significant adverse facts regarding Medpace's backlog cancellation rate, leading to overly optimistic growth expectations among investors.
- Performance Decline: On February 9, 2026, Medpace reported a fourth-quarter book-to-bill ratio of 1.04, significantly below the guidance of 1.15, causing the stock price to plummet from $530.35 to $446.05, a decline of over 15.9%.
- Investor Rights: Affected investors have until June 8, 2026, to request to be appointed as lead plaintiff, with participation in any recovery requiring no out-of-pocket costs, highlighting the firm's commitment to protecting investor rights.
See More
